10 assets in Vaginal Adenocarcinoma

Therapeutic assets addressing Vaginal Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
e7 tcr-t cells Vaginal Adenocarcinoma	Christian Hinrichs	P2	CCC (53)
Ipilimumab Vaginal Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Vaginal Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Tsc-200-A0201 Vaginal Adenocarcinoma	TScan Therapeutics, Inc.	P1	CC (43)
Tsc-201-B0702 Vaginal Adenocarcinoma	TScan Therapeutics, Inc.	P1	CC (43)
Tsc-202-A0201 Vaginal Adenocarcinoma	TScan Therapeutics, Inc.	P1	CC (43)
Tsc-203-A0201 Vaginal Adenocarcinoma	TScan Therapeutics, Inc.	P1	CC (43)
Tsc-204-A0101 Vaginal Adenocarcinoma	TScan Therapeutics, Inc.	P1	CC (43)
Tsc-204-A0201 Vaginal Adenocarcinoma	TScan Therapeutics, Inc.	P1	CC (43)
Tsc-204-C0702 Vaginal Adenocarcinoma	TScan Therapeutics, Inc.	P1	CC (43)